Filter by Category: Antimicrobial Surveillance

Global trends in an antimicrobial resistance surveillance system: Results from the MYSTIC Programme.

Global trends in an antimicrobial resistance surveillance system: Results from the MYSTIC Programme. by Pfaller MA and Jones RN published in Clin. Microbiol. Infect. 2000; 6 (Suppl 1): 74

MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: Resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas).

MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: Resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas). by Pfaller MA and Jones RN published in J. Antimicrob. Chemother. 2000; 46 (Suppl T2): 25-37

Detection of emerging resistance patterns within longitudinal surveillance systems: Data sensitivity and microbial susceptibility. MYSTIC Advisory Board. Meropenem Yearly Susceptibility Test Information Collection.

Detection of emerging resistance patterns within longitudinal surveillance systems: Data sensitivity and microbial susceptibility. MYSTIC Advisory Board. Meropenem Yearly Susceptibility Test Information Collection. by Jones RN published in J. Antimicrob. Chemother. 2000; 46 (Suppl T2): 1-8

Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2,000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999).

Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2,000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999). by Deshpande LM and Jones RN published in Diagn. Microbiol. Infect. Dis. 2000; 37 (2): 139-142

A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia.

A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. by Bhavnani SM, Drake JA, Forrest A, Deinhart JA, Jones RN, Biedenbach DJ and Ballow CH published in Diagn. Microbiol. Infect. Dis. 2000; 36 (3): 145-158

Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia.

Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia. by Jones RN published in Clin. Infect. Dis. 1999; 29 (3): 495-502

Summation: β-lactam resistance surveillance in the Asia-Western Pacific region.

Summation: β-lactam resistance surveillance in the Asia-Western Pacific region. by Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 333-338

In vitro evaluation of broad-spectrum β-lactams in the Philippines medical centers: Role of fourth-generation cephalosporins. The Philippines Antimicrobial Resistance Study Group.

In vitro evaluation of broad-spectrum β-lactams in the Philippines medical centers: Role of fourth-generation cephalosporins. The Philippines Antimicrobial Resistance Study Group. by Johnson DM, Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 291-297

Comparative activity of clinafloxacin and nine other compounds tested against 2,000 contemporary clinical isolates from patients in United States hospitals.

Comparative activity of clinafloxacin and nine other compounds tested against 2,000 contemporary clinical isolates from patients in United States hospitals. by Deshpande LM, Diekema DJ, and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (1): 81-88

In vitro evaluation of cefepime and other broad-spectrum β-lactams in Taiwan medical centers. The Taiwan Antimicrobial Resistance Study Group.

In vitro evaluation of cefepime and other broad-spectrum β-lactams in Taiwan medical centers. The Taiwan Antimicrobial Resistance Study Group. by Biedenbach DJ, Johnson DM and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 299-305